Chemomab Therapeutics

CMMBNasdaq Israel Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$16.520 M

$2.28 -4.20%

Close of 23 Sept 2026

Revenue

—

Not reported

Earnings

-$8.99M

Loss-making

Shares outstanding

575,381,320

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 500 →

#406BiofronteraBFRI$17.1M
#407Allarity TherapeuticsALLR$16.5M
#408Chemomab TherapeuticsCMMB$16.5M
#409NewcelXNCEL$16.5M
#410Vistagen TherapeuticsVTGN$16.3M

What if Chemomab Therapeutics were worth as much as…

Open the what-if tool →

Gold $29.8T

$4,119,313

Per share 1,806,716× higher

Bitcoin $1.69T

$233,813.42

Per share 102,550× higher

Nvidia $5.43T

$750,080.75

Per share 328,983× higher

Or at a round number

$20.0M $50.0M $100.0M $200.0M

Where these numbers come from

Share counts and financials for Chemomab Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 24 Sept 2026. Read the methodology.